Cencora Quarterly Income Statement
NYSE: CORHealth CareOther PharmaceuticalsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Cencora revenue and earnings
In the quarter ended Jun 30, 2026, Cencora generated $84.75 billion in revenue, up 5.1% from the same quarter a year earlier. Net income was $763.5 million (+11.1% year over year), for a net margin of 0.9% versus a median of 0.9% in the prior 5 quarters. Gross margin was 4.3% (up from 3.6%) and operating margin 1.3%.
Diluted earnings per share came in at $3.94, up from $3.52.
Summary generated from market data by MetaCap's automated system. Methodology
Cencora income statement (quarterly)
| Quarter (USD) | Q3 20262026-06-30 | Q2 20262026-03-31 | Q1 20262025-12-31 | Q4 20252025-09-30 | Q3 20252025-06-30 | Q2 20252025-03-31 | Q1 20252024-12-31 | Q4 20242024-09-30 | Q3 20242024-06-30 | Q2 20242024-03-31 | Q1 20242023-12-31 | Q4 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 84.75B | 78.36B | 85.93B | 83.73B | 80.66B | 75.45B | 81.49B | 79.05B | 74.24B | 68.41B | 72.25B | 68.92B |
| Revenue growth (YoY) | +5.07% | +3.85% | +5.45% | +5.92% | +8.65% | +10.29% | +12.78% | +14.69% | +10.90% | +7.81% | +14.97% | +12.67% |
| Cost of Revenue | 81.15B | 74.77B | 82.86B | 80.77B | 77.76B | 72.39B | 78.93B | 76.56B | 71.83B | 65.88B | 69.78B | 66.67B |
| Gross Profit | 3.61B | 3.59B | 3.07B | 2.95B | 2.91B | 3.06B | 2.56B | 2.49B | 2.41B | 2.54B | 2.47B | 2.25B |
| Operating Expenses | 2.28B | 2.11B | 1.93B | 1.88B | 1.80B | 1.72B | 1.59B | 2.37B | 1.74B | 1.98B | 1.65B | 1.78B |
| Selling, General & Admin | 2.13B | 1.98B | 1.80B | 1.75B | 1.67B | 1.60B | 1.47B | 1.49B | 1.38B | 1.39B | 1.40B | 1.39B |
| Operating Income | 1.12B | 1.14B | 760.45M | 18.50M | 867.65M | 1.04B | 706.25M | 126.64M | 672.48M | 553.26M | 822.88M | 476.94M |
| Other Income (Expense) | 16.88M | 1.09B | 20.60M | -127.71M | 110.42M | -3.55M | -57.87M | 19.51M | -12.81M | -22.06M | 1.09M | 30.42M |
| Pretax Income | 996.39M | 2.09B | 708.64M | -187.04M | 896.28M | 928.66M | 620.45M | 125.18M | 628.33M | 467.07M | 783.40M | 446.42M |
| Income Tax | 219.73M | 459.04M | 142.51M | 146.03M | 206.53M | 211.24M | 126.73M | 117.71M | 140.74M | 45.86M | 180.39M | 97.44M |
| Net Income | 763.52M | 1.64B | 559.65M | -339.70M | 687.40M | 717.87M | 488.60M | 3.38M | 483.46M | 420.77M | 601.50M | 350.56M |
| Net Income growth (YoY) | +11.07% | +128.64% | +14.54% | -10144.47% | +42.18% | +70.61% | -18.77% | -99.04% | +0.81% | -3.36% | +25.38% | +18.94% |
| EPS (Basic) | 3.95 | 8.44 | 2.88 | -1.75 | 3.55 | 3.70 | 2.52 | 0.04 | 2.44 | 2.11 | 3.01 | 1.75 |
| EPS (Diluted) | 3.94 | 8.40 | 2.87 | -1.74 | 3.52 | 3.68 | 2.50 | 0.04 | 2.42 | 2.09 | 2.98 | 1.72 |
| Shares Outstanding (Basic) | 193.15M | 194.54M | 194.22M | — | 193.82M | 193.80M | 193.76M | — | 198.26M | 199.41M | 200.08M | — |
| Shares Outstanding (Diluted) | 193.94M | 195.38M | 195.32M | — | 195.23M | 195.09M | 195.19M | — | 200.05M | 201.18M | 201.84M | — |
| EBITDA | 1.39B | 1.39B | 1.02B | 277.27M | 1.12B | 1.30B | 984.75M | 237.88M | 786.75M | 665.83M | 932.98M | 588.43M |
| Gross Margin | 4.26% | 4.58% | 3.58% | 3.53% | 3.60% | 4.06% | 3.14% | 3.15% | 3.25% | 3.71% | 3.42% | 3.27% |
| Operating Margin | 132.00% | 146.00% | 88.00% | 2.00% | 108.00% | 137.00% | 87.00% | 16.00% | 91.00% | 81.00% | 114.00% | 69.00% |
| Net Margin | 90.00% | 2.09% | 65.00% | -41.00% | 85.00% | 95.00% | 60.00% | 0.00% | 65.00% | 62.00% | 83.00% | 51.00% |
This table shows 12 quarterly periods of Cencora's income statement, from Q3 2026 back to Q4 2023, across 18 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow COR's reporting calendar. What is a income statement?